Search
Filters
Clear All
  • 13
  • 48
  • 2
  • 691

Phase

  • 1
  • 13
  • 11
  • 48
  • 9
  • 53
  • 6
  • 581
  • 687
  • 313

Found 754 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

M
Michael Ferguson, MD
1-17 years
All genders
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
Learn More

A Phase 2 Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

T
Theodore Logan, MD
18-70 years
All genders
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) with Lifileucel infusion (LN-144) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen.
Learn More

Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder (ADAPT)

N
Nabil Adra, MD
18-100 years
All genders
The main purpose of this phase 1 trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy. The overall goal of this trial is to see if the risk of your cancer coming back can be decreased with …
Learn More

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

A
Ahmad Al-Hader, MD
18-100 years
All genders
This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body.
Learn More

Assessing tobacco use and cessation support among patients with non-tobacco related cancers

N
Nasser Hanna, MD
18-100 years
All genders
The purpose of this study is to estimate how many patients currently smoke tobacco who are diagnosed with breast, colon, and prostate cancer, to understand what patients know about the harms of continuing to smoke, and to learn about any previous efforts to quit.
Learn More

The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (the CHEC-SC study)

C
Clement Ren, MD
1-100 years
All genders
This study will collect contemporary sweat chloride values from cystic fibrosis patients prescribed and currently receiving commercially approved CFTR modulator therapies.
Learn More

Total Cancer Care: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer

B
Bryan Schneider, MD
2-100 years
All genders
The purpose of this research study is to collect and store biospecimens and personal health information to use in future research studies. This research study is to build a large database (of information and specimens) to find better ways to prevent, diagnose and treat cancer.
Learn More

The effect of mindsets on novice piano learning

G
Gregory Dam
18-100 years
All genders
The purpose of this research is to assess how well people learn to play the piano.
Learn More

Early Development of Action Understanding

B
Bennett Bertenthal
1-1 years
All genders
The goal of this study is to learn more about how infants perceive and represent observed actions.
Learn More

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

G
Greg Durm, MD
18-100 years
All genders
This study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in patients who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Learn More
351 - 360 of 754